期刊文献+

大剂量阿托伐他汀在急性冠脉综合症患者介入术后的疗效观察 被引量:2

下载PDF
导出
摘要 目的观察急性冠脉综合症(ACS)患者行经皮冠状动脉介入治疗(PCI)后应用大剂量阿托伐他汀治疗的疗效及安全性。方法选择82例成功进行PCI术ACS患者随机分为2组,治疗组在常规治疗基础上,应用阿托伐他汀80mg/d;对照组应用阿托伐他汀20mg/d,观察2组患者用药后4、12周的心脏缺血事件、血脂和高敏C反应蛋白(hs-CRP)及不良反应。结果心脏缺血事件的发生率治疗组低于对照组(P<0.05)。血脂和hs-CRP水平降低治疗组好于对照组(P<0.05)。服药1个月后2组(治疗组7例/对照组5例)均有谷丙转氨酶(ALT)轻度升高(<2倍),2组差异无统计学意义。结论大剂量阿托伐他汀治疗急性冠脉综合症患者介入术后疗效显著,无严重的不良反应。
出处 《中外医疗》 2011年第8期105-105,107,共2页 China & Foreign Medical Treatment
  • 相关文献

参考文献5

  • 1Serruys PW,Feyter P,Macaya C,et al.Fluvastatin for prevention of cardiac events following successful first percutaneous coronary inter-vention:a randomized controlledtrial[J].JAMA,2002,287(1): 3215- 3222. 被引量:1
  • 2Saleh Nawsad MD,Svane Bertil MD,Jens MD.Stent implantation, but not pathogen burden,is associated with plasma C-reactive pro- tein and interleukin-6 levels after percutaneous coronary inter- vention in patients with stable angina pectoris[J].Am Heart J, 2005,149(5):876- 882. 被引量:1
  • 3董亚琳,董卫华.他汀类药物的研究进展[J].中国新药杂志,2003,12(3):175-178. 被引量:62
  • 4Adelmouttalebl,Danchin H.C-reactive protein and coronaryarter ydisease:Additional evidence of the implication an inflammatory process in acute coronary syndromes[J].Am Heart J,1999,137(2): 346- 351. 被引量:1
  • 5Rifal N,Rider PM.High sensitivity reactive protein:a novel and promising marker of coronary heart disease[J].Clinical Chemistry, 2001. 被引量:1

二级参考文献5

共引文献61

同被引文献33

  • 1LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med, 2005, 352(14) :1425-1435. 被引量:1
  • 2Cannon CP,Braunwald E, McCabe CH, et al. Intensive versts moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med, 2004, 350(15) :1495-1504. 被引量:1
  • 3Amarenco P,Bogousslavsky J, Callahan A 3rd, et at. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med, 2006, 355(6):549-559. 被引量:1
  • 4Higgins JP,Green S. Cochrane Handbook for Systematic Reviews of Interventions (Version 5. 1.0). Available at: http://www. cochrane handbook, org. 被引量:1
  • 5Yu XL,Zhang H J, Ren SD, et al. Effects of loading dose of atorvastatin before percutaneous coronary intervention on periprocedural myocardial injury. Coron Artery Dis, 2011, 22 ( 1 ) :87-91. 被引量:1
  • 6Zhao Z, Geng J, Ge ZM, et al. Efficacy and safety of atorvastatin during early hospitalization in elderly patients with unstable angina. Clin Exp Pharmacol Physiol, 2009, 36(5-6) :554-558. 被引量:1
  • 7Jang Y,Zhu J, Ge J, et al. Preloading with atorvastatin before pcrcutaneous coronary intervention in statin-na? ve Asian patients with non-ST elevation acute coronary syndromes: A randomized study. J Cardiol, 2014, 63 ( 5 ) : 335-343. 被引量:1
  • 8杨远志.冠状动脉粥样硬化性心脏病心绞疼的临床治疗体会.中国保健营养(中旬刊),2012,23(11):472. 被引量:1
  • 9Athyros VG, Tziomalos K, Karagiannis A, et al. Atorvastatin : safety and tolerability. Expert Opin Drug Saf, 2010, 9(4) :667- 674. 被引量:1
  • 10张青,贾春芳,李艳芳.大剂量阿托伐他汀治疗冠心病并发高脂血症的有效性与安全性[J].心脏杂志,2008,20(2):187-189. 被引量:10

引证文献2

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部